Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Michael N Dalili, José A López-López, Deborah M Caldwell, Kyla H Thomas, Mark Stevenson, David Phillippo, Edna Keeney, Nicky J Welton, Marcus R. Munafò
Publikováno v:
Keeney, E, Welton, N J, Stevenson, M, Dalili, M N, López-López, J A, Caldwell, D M, Phillippo, D M, Munafò, M R & Thomas, K H 2021, ' Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events ', Value in Health, vol. 24, no. 6, pp. 780-788 . https://doi.org/10.1016/j.jval.2020.12.012
Value in Health
Value in Health
OBJECTIVES: Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replacement therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each other.
Autor:
Edith A. Perez, Hans-Peter Goertz, Joseph B. Babigumira, Louis P. Garrison, Solomon J. Lubinga, C. Tournier
Publikováno v:
Value in Health. 22:408-415
Objective The APHINITY trial assessed the effectiveness and the safety of adding pertuzumab to trastuzumab and chemotherapy (THP) compared to trastuzumab and chemotherapy (TH) in the adjuvant management of human epidermal growth factor 2-positive (HE
Publikováno v:
Value in Health. 20:705-709
Background Economic evaluations often measure an intervention effect with mean overall survival (OS). Emerging types of cancer treatments offer the possibility of being "cured" in that patients can become long-term survivors whose risk of death is th
Autor:
Joan G. Meeder, Matthijs Versteegh, Maureen P.M.H. Rutten-van Mölken, Rudolf A. de Boer, Gerard C.M. Linssen, Jolanda M.A. Koenders, Isaac Corro Ramos
Publikováno v:
Value in Health, 20(10), 1260-1269. ELSEVIER SCIENCE INC
Value in Health. Elsevier Ltd.
Value in Health. Elsevier Ltd.
Objectives: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in